Top

Published in:

01-11-2023 | Fingolimod | Letter to the Editors

Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod

Authors: Lina Jeantin, Natalia Shor, Maud Pallix-Guyot, Damien Roos-Weil, Agnès Bellanger, Magali Le Garff-Tavernier, Caroline Papeix, Nicolas Weiss, Valérie Pourcher

Published in: Journal of Neurology | Issue 2/2024

Excerpt

Dear Sirs, …

Kleinschmidt-DeMasters BK (2005) Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. N Engl J Med 353:369CrossRefPubMed

Brinkmann V, Davis MD, Heise CE et al (2002) The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors. J Biol Chem 277:21453–21457. https://doi.org/10.1074/jbc.C200176200CrossRefPubMed

Berger JR, Cree BA, Greenberg B et al (2018) Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90:e1815–e1821. https://doi.org/10.1212/WNL.0000000000005529CrossRefPubMedPubMedCentral

Sriwastava S, Chaudhary D, Srivastava S et al (2022) Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol 269:1678–1687. https://doi.org/10.1007/s00415-021-10910-1CrossRefPubMed

Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med 380:1597–1605. https://doi.org/10.1056/NEJMoa1815039CrossRefPubMed

Roos-Weil D, Weiss N, Guihot A et al (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458–2465. https://doi.org/10.1007/s00415-021-10414-yCrossRefPubMed

Boumaza X, Bonneau B, Roos-Weil D et al (2022) Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors. Ann Neurol. https://doi.org/10.1002/ana.26512CrossRefPubMedPubMedCentral

Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467–480. https://doi.org/10.1016/S1474-4422(18)30040-1CrossRefPubMed

Barber DL, Wherry EJ, Masopust D et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687. https://doi.org/10.1038/nature04444CrossRefPubMed

10.

Tan CS, Bord E, Broge TA et al (2012) Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy. JAIDS J Acquir Immune Defic Syndr 60:244–248. https://doi.org/10.1097/QAI.0b013e31825a313cCrossRefPubMed

11.

Lombardo-del Toro P, Bragado-Trigo I, Arroyo P et al (2023) Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim. J Neurol. https://doi.org/10.1007/s00415-023-11865-1CrossRefPubMed

12.

Redelman-Sidi G, Michielin O, Cervera C et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 24:S95–S107. https://doi.org/10.1016/j.cmi.2018.01.030CrossRefPubMedPubMedCentral

13.

Tyler KL, Vollmer TL (2017) To PLEX or not to PLEX in natalizumab-associated PML. Neurology 88:1108–1109. https://doi.org/10.1212/WNL.0000000000003747CrossRefPubMed

14.

Landi D, De Rossi N, Zagaglia S et al (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88:1144–1152. https://doi.org/10.1212/WNL.0000000000003740CrossRefPubMed

15.

Mickeviciene D, Baltusiene A, Afanasjeva B et al (2022) Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A Case Report. BMC Neurol 22:306. https://doi.org/10.1186/s12883-022-02839-3CrossRefPubMedPubMedCentral

Title: Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod
Authors: Lina Jeantin
Natalia Shor
Maud Pallix-Guyot
Damien Roos-Weil
Agnès Bellanger
Magali Le Garff-Tavernier
Caroline Papeix
Nicolas Weiss
Valérie Pourcher
Publication date: 01-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Fingolimod
Multiple Sclerosis
Natalizumab
Cranial MRI
Ocrelizumab
Ocrelizumab
Checkpoint Inhibitors
Published in: Journal of Neurology / Issue 2/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12055-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2024

Recurrence and long-term outcomes of Tolosa-Hunt syndrome

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Cognitive impairment associated with cerebellar volume loss in spinocerebellar ataxia type 3

Implementation of a 7T Epilepsy Task Force consensus imaging protocol for routine presurgical epilepsy work-up: effect on diagnostic yield and lesion delineation

Peering further into the mind’s eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis

Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis